{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Double+Blind&page=58",
    "query": {
      "condition": "Double Blind",
      "page": 58
    },
    "page_size": 10
  },
  "pagination": {
    "page": 58,
    "page_size": 10,
    "total_count": 18300,
    "total_pages": 1830,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Double+Blind&page=59&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Double+Blind&page=57&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T04:49:43.970Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06223880",
      "title": "A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "AXS-05",
          "type": "DRUG"
        },
        {
          "name": "Bupropion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Axsome Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 350,
      "start_date": "2023-12-27",
      "completion_date": "2026-03",
      "has_results": false,
      "last_update_posted_date": "2025-01-23",
      "last_synced_at": "2026-11-19T04:49:43.970Z",
      "location_count": 40,
      "location_summary": "Bellflower, California • Lafayette, California • Oceanside, California + 34 more",
      "locations": [
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06223880"
    },
    {
      "nct_id": "NCT07126262",
      "title": "A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypochondroplasia"
      ],
      "interventions": [
        {
          "name": "Vosoritide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Months",
        "maximum_age": "36 Months",
        "sex": "ALL",
        "summary": "0 Months to 36 Months"
      },
      "enrollment_count": 60,
      "start_date": "2025-07-30",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-11-19T04:49:43.970Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Oakland, California + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07126262"
    },
    {
      "nct_id": "NCT00942188",
      "title": "A Study of LY2189102 in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "LY2189102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "20 Years to 75 Years"
      },
      "enrollment_count": 106,
      "start_date": "2009-06",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2019-09-18",
      "last_synced_at": "2026-11-19T04:49:43.970Z",
      "location_count": 18,
      "location_summary": "Mobile, Alabama • Anaheim, California • Chula Vista, California + 15 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00942188"
    },
    {
      "nct_id": "NCT02601703",
      "title": "To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Tacrolimus Ointment 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Protopic® ointment, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Placebo of Tacrolimus Ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glenmark Pharmaceuticals Ltd. India",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1110,
      "start_date": "2015-08",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2019-07-31",
      "last_synced_at": "2026-11-19T04:49:43.970Z",
      "location_count": 60,
      "location_summary": "Tempe, Arizona • Anaheim, California • Bell Gardens, California + 43 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bell Gardens",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02601703"
    },
    {
      "nct_id": "NCT04948827",
      "title": "A First-in-Human Study of SBP-9330 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "SBP-9330",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Camino Pharma, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 90,
      "start_date": "2021-07-20",
      "completion_date": "2023-03-06",
      "has_results": true,
      "last_update_posted_date": "2024-04-16",
      "last_synced_at": "2026-11-19T04:49:43.970Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04948827"
    },
    {
      "nct_id": "NCT02512042",
      "title": "Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Test-Brinzolamide 1% Ophthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "Reference-Brinzolamide 1% Ophthalmic suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 973,
      "start_date": "2015-04",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2020-03-02",
      "last_synced_at": "2026-11-19T04:49:43.970Z",
      "location_count": 10,
      "location_summary": "Newport Beach, California • Largo, Florida • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02512042"
    },
    {
      "nct_id": "NCT00089986",
      "title": "GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sepsis"
      ],
      "interventions": [
        {
          "name": "Intravenous GR270773- Phospholipid Emulsion",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1415,
      "start_date": "2004-09-01",
      "completion_date": "2007-04-15",
      "has_results": true,
      "last_update_posted_date": "2017-08-21",
      "last_synced_at": "2026-11-19T04:49:43.970Z",
      "location_count": 132,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 110 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089986"
    },
    {
      "nct_id": "NCT05283486",
      "title": "Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcopenia",
        "Frailty",
        "Aging"
      ],
      "interventions": [
        {
          "name": "MYMD-1 600MG",
          "type": "DRUG"
        },
        {
          "name": "MYMD-1 750mg",
          "type": "DRUG"
        },
        {
          "name": "MYMD-1 900mg",
          "type": "DRUG"
        },
        {
          "name": "MYMD-1 1050mg",
          "type": "DRUG"
        },
        {
          "name": "placebo 600mg",
          "type": "DRUG"
        },
        {
          "name": "placebo 750mg",
          "type": "DRUG"
        },
        {
          "name": "placebo 900mg",
          "type": "DRUG"
        },
        {
          "name": "placebo 1050mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TNF Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "65 Years to 99 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-02-01",
      "completion_date": "2023-06-07",
      "has_results": false,
      "last_update_posted_date": "2023-10-30",
      "last_synced_at": "2026-11-19T04:49:43.970Z",
      "location_count": 3,
      "location_summary": "Clearwater, Florida • Tampa, Florida • Baltimore, Maryland",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283486"
    },
    {
      "nct_id": "NCT02045732",
      "title": "A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "PF-06342674 0.25 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PF-06342674 1.5 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PF-06342674 6.0 mg/kg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 4,
      "start_date": "2014-09",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-01-16",
      "last_synced_at": "2026-11-19T04:49:43.970Z",
      "location_count": 8,
      "location_summary": "Albany, New York • Latham, New York • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Albany",
          "state": "New York"
        },
        {
          "city": "Latham",
          "state": "New York"
        },
        {
          "city": "Latham",
          "state": "New York"
        },
        {
          "city": "Latham",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02045732"
    },
    {
      "nct_id": "NCT03051516",
      "title": "HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "High Grade Anal Canal Intraepithelial Neoplasia",
        "High Grade Vulvar Squamous Intraepithelial Lesion"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Recombinant Human Papillomavirus Nonavalent Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "27 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "27 Years to 69 Years"
      },
      "enrollment_count": 188,
      "start_date": "2017-08-01",
      "completion_date": "2022-12-31",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-11-19T04:49:43.970Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Seattle, Washington",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03051516"
    }
  ]
}